Dr. Michael Murphy profile page

Biacore Application Scientist

at Cytiva

Michael began employment at Cytiva in the Biacore applications team in 2004 to support the mid-Atlantic region of the United States. He received his Ph.D. in Biophysics from Case Western Reserve University in 2000. He has extensive research experience with ÄKTA and Biacore systems for four years to develop and characterize aptamers against various protein targets at Berkeley Lab’s Joint Genome Institute.

Got a Question for Dr. Michael Murphy?

Get in touch using the contact form linked here and we’ll get back to you shortly.

Published Content

Total: 1

Webinar

Label-Free Protein Activity Quantification for Drug Production and QC

On-Demand

Biotherapeutic drugs are complex and can perform their function through interactions with more than one target molecule. During development and quality control, a range of analytical technologies are used to characterize biotherapeutic drugs in terms of their structural integrity and activity. Ligand-binding assays are relevant for characterization and quantitation of the functional drug, however current analytical approaches may no longer be sufficient for analysis of emerging drug modalities.
Biacore™ assays are based on ligand binding and used in development and characterization of drug product using active concentration measurements, target binding, potency (E50)
and Fc receptor (FcR) analysis.